Business Context and Reporting Period
This Form 6-K filing by Anbio Biotechnology, a Cayman Islands exempted company, covers the month of February 2025. The report details the successful completion of the Company's Initial Public Offering (IPO) on The Nasdaq Global Market under the ticker symbol "NNNN".
Key Financial Metrics
The filing focuses on the IPO transaction rather than historical financial performance. Key transaction metrics include:
- Shares Sold: 1,600,000 Class A ordinary shares.
- Offering Price: $5.00 per share.
- Total Gross Proceeds: $8,000,000 (calculated from shares and price).
- Underwriter: AC Sunshine Securities LLC.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions as this is a transactional report regarding the IPO closing.
Material Changes
The primary material change is the Company's transition to a publicly traded entity. Key milestones include:
- February 18, 2025: Entered into the underwriting agreement and the SEC declared the Registration Statement (Form F-1) effective.
- February 19, 2025: Shares commenced trading on The Nasdaq Global Market.
- February 20, 2025: The IPO officially closed.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, management commentary on future operations, or a detailed risk factor section. It includes a standard disclaimer stating that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful. The document incorporates by reference press releases regarding the pricing and closing of the IPO.
Investor Verification Checklist
- Verify the final net proceeds after deducting underwriting discounts and offering expenses.
- Review the full Underwriting Agreement (Exhibit 1.1) for lock-up periods and indemnification terms.
- Confirm the use of proceeds as detailed in the original Form F-1 Registration Statement.
- Check subsequent trading volume and price stability of the "NNNN" ticker on Nasdaq.